Liquid Biotech USA has entered a research agreement with the University of Pennsylvania to study and utilise the circulating tumour cells (CTCs)-derived information to develop anti-cancer therapies through its precision medicine platform.
According to the agreement, Liquid Biotech will fund the study to be able to understand the changes in CTC levels in correlation with clinical outcomes in cancer patients undergoing different anti-cancer therapies. The derived data will be used to develop a therapeutic and decision making study to guide anti-cancer therapies.
Entourage Phytolab S. A. has announced that it will enter an agreement with Canopy Growth Corporation to develop cannabis-based pharmaceutical medical products for Brazilian and international markets and also to conduct clinical trials pursuant to the registration of the medicines.
Pursuant to the agreement, Entourage Phytolab will be responsible to develop the standardised cannabis extracts for pre-clinical and clinical trials. The two partners will use medical cannabis provided by Bedrocan Brazil S.A. to develop innovative cannabis medicine products and begin clinical trials in 2016 with a target submission for market approval by National Health Surveillance Agency by 2018.
Mayne Pharma plans to raise gross proceeds of $212.24m through the private placement of 191.3m of its shares.
The company intends use the proceeds for the acquisition of US generic products portfolio from Teva Pharma and Allergan and also to increase the working capital.
Pharmaceutical company Pfizer Inc. and clinical operations service provider Inventive Health Inc. have entered a partnership to support Pfizer’s product portfolio by expanding clinical operations services.
According to the agreement, Inventive Health will expand its clinical operations services presence and support Pfizer with therapeutic excellence in the areas of oncology, pain, neurosciences, respiratory, data and technology efficiencies.
Mayne Pharma has entered a binding agreement with Teva Pharma and Allergan for the acquisition of their US generics product portfolio for a purchase consideration of $625m.
The transaction enables Mayne Pharma to expand its generic products portfolio and is expected to add $237m to its FY17 net sales.
Image: Mayne Pharma has entered a binding agreement with Teva Pharma and Allergan. Photo : Courtesy of Raysonho.